Margaret A. Alexander sold $17k of OVID
President and CEO at Ovid Therapeutics Inc.. 11,656 shares at an average of $1.45, traded Feb 23, 2026, filed Mar 2, 2026.
Score components
- +25RoleCEO
- 0Trade size$17k at market
- +5Share of holdings soldSold 16% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +30.1%, 3m +54.2%, 6m +60.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002036798-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 23, 2026 | SOpen-market sale Common Stock | -11,656 | $1.45 | $17k | 61,750 | Mar 2, 2026 |
| Feb 26, 2026 | AGrant or award Employee Stock Option (Right to Buy)derivative | +1,435,000 | $0.00 | $0 | 1,435,000 | Mar 2, 2026 |
Related signals
Other insiders at Ovid Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Ovid Therapeutics Inc. | Jeffrey A Rona CBFO | $12k 8,541 shares | -9% | |
| 20Weak | OVIDsell Ovid Therapeutics Inc. | Margaret A. Alexander President and COO | $2,956 5,279 shares | -7% | |
| 26Weak | OVIDbuy Ovid Therapeutics Inc. | Margaret A. Alexander President and COO | $4,971 6,810 shares | +24% | |
| 35Weak | OVIDbuy Ovid Therapeutics Inc. | Jeremy M Levin CEO | $50k 18,248 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.